Olaparib attenuates the oxLDL-mediated increase in pro-IL-1β and pro-IL-18 protein expression.

Abstract

THP-1 monocytes were exposed to oxLDL, the PARP inhibitor olaparib (Olapa), or the NLRP3 inhibitor MCC950 (MCC), individually or in combination as indicated. Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-pro-IL-1β (top), anti-pro-IL-18 (middle) or anti-vinculin antibody (bottom, for loading control). The densities of pro-IL-1β, pro-IL-18 over vinculin were quantified by densitometry and normalized to vehicle. The band densities, relative to vinculin, were quantified using ImageJ (NIH, Bethesda, MD). N = 4/group, *P<0.05 vs vehicle, #P<0.05 vs oxLDL only, one-way ANOVA, Newman-Keuls test.</p